Evoke Pharma, Inc.【EVOK】 業績推移・財務諸表

(単位:千ドル) 3Q13 4Q13 1Q14 2Q14 3Q14 4Q14 1Q15 2Q15 3Q15 4Q15 1Q16 2Q16 3Q16 4Q16 1Q17 2Q17 3Q17 4Q17 1Q18 2Q18 3Q18 4Q18 1Q19 2Q19 3Q19 4Q19 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25
現金同等物 23,738 24,196 21,835 16,045 12,176 14,155 11,692 9,883 10,738 8,691 6,099 4,129 10,379 9,007 14,654 12,556 10,412 7,679 5,405 6,531 6,567 5,319 4,028 7,440 6,504 5,663 4,133 7,990 6,280 8,068 18,185 16,720 11,141 9,144 7,701 13,500 12,400 9,843 8,212 7,006 6,000 4,739 9,702 9,200 11,339 13,600 12,624
現金 + 有価証券 23,738 24,196 21,835 16,045 12,176 14,155 11,692 9,883 10,738 8,691 6,099 4,129 10,379 9,007 14,654 12,556 10,412 7,679 5,405 6,531 6,567 5,319 4,028 7,440 6,504 5,663 4,133 7,990 6,280 8,068 18,185 16,720 11,141 9,144 7,701 13,500 12,400 9,843 8,212 7,006 6,000 4,739 9,702 9,200 11,339 13,600 12,624
商品及び製品 - - - - - - - - - - - - - - - - - - - - - - - - - - - - 86 236 236 234 225 185 278 268 220 289 364 513 504 481 588 544 493 445 532
流動資産合計 23,738 24,430 22,011 16,934 13,308 15,248 12,574 10,607 11,674 9,524 6,872 4,636 10,813 9,282 14,826 13,144 10,747 7,930 5,584 6,626 7,006 5,648 4,259 7,561 7,291 6,245 4,532 8,195 6,714 9,280 19,176 17,472 11,600 10,560 9,026 14,404 13,256 11,722 9,947 8,926 7,839 6,826 12,453 12,136 14,038 17,237 16,230
固定資産合計 0 555 555 88 82 53 47 0 7 7 0 0 0 11 11 11 11 11 0 0 11 11 103 69 35 150 105 71 36 153 119 84 49 12 0 0 153 129 91 52 13 241 0 0 115 281 145
総資産 23,738 24,986 22,567 17,023 13,390 15,301 12,621 10,607 11,682 9,532 6,872 4,636 10,813 9,294 14,838 13,155 10,759 7,941 5,584 6,626 7,018 5,659 4,362 7,631 7,327 6,395 4,637 8,267 6,750 9,434 19,295 17,557 11,649 10,573 9,026 14,404 13,410 11,851 10,039 8,979 7,852 7,068 12,453 12,136 14,153 17,519 16,375
一年内返済予定の長期借入金 1,069 1,442 1,442 - - 150 712 1,251 - 146 708 4,399 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
流動負債合計 2,637 2,284 2,943 1,837 1,685 1,871 2,499 3,194 2,006 1,834 2,434 6,163 1,011 1,411 1,135 1,879 2,648 2,074 1,195 1,265 1,610 1,634 1,287 1,285 2,154 2,015 1,716 6,640 6,621 7,535 6,248 6,231 1,390 1,405 1,356 1,353 1,877 1,654 1,677 2,081 2,240 3,035 8,956 9,471 9,766 10,380 10,451
長期借入金 1,878 1,511 1,156 - - 4,241 3,688 3,101 4,368 4,233 3,680 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
固定負債合計 1,878 1,518 1,172 16 14 4,241 3,688 3,101 4,368 4,233 3,680 0 5,098 4,095 5,768 4,506 6,050 3,701 0 0 0 0 - - - - - 2,000 2,053 5,112 5,235 5,360 5,486 5,612 5,735 5,860 5,999 6,112 6,235 6,360 6,486 6,612 0 0 0 100 83
総負債 4,515 3,803 4,116 1,853 1,700 6,113 6,187 6,296 6,374 6,067 6,115 6,163 6,110 5,506 6,904 6,385 8,699 5,776 1,195 1,265 1,610 1,634 - - - - - 8,640 8,674 12,648 11,484 11,591 6,876 7,018 7,092 7,213 7,877 7,766 7,913 8,441 8,726 9,648 8,956 9,471 9,766 10,480 10,534
資本金及び資本剰余金 40,297 43,874 44,098 44,363 44,710 0 0 0 0 0 0 0 1 1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 3 3 3 0 3 0 0 0 0 0 0 0 0 0 0 0 0
利益剰余金 - - - -29,194 -33,020 -35,940 -39,460 -42,702 -45,437 -48,061 -51,287 -54,257 -57,282 -58,810 -63,862 -65,488 -70,731 -71,039 -73,022 -75,325 -76,845 -78,605 -80,571 -82,685 -84,313 -85,731 -87,521 -94,489 -96,618 -98,886 -101,491 -103,782 -105,751 -107,424 -109,597 -111,831 -113,844 -115,648 -117,891 -119,759 -121,453 -123,440 -125,020 -126,287 -127,599 -128,792 -130,098
株主資本 19,222 21,183 18,451 15,169 11,690 9,188 6,433 4,311 5,307 3,464 757 -1,527 4,703 3,787 7,933 6,769 2,059 2,165 4,389 5,360 5,407 4,025 3,075 6,346 5,173 4,380 2,921 -374 -1,924 -3,215 7,811 5,965 4,773 3,555 1,934 7,191 5,532 4,084 2,126 538 -874 -2,580 3,497 2,664 4,387 7,038 5,841
有利子負債合計 2,948 2,954 2,599 - - 4,323 4,401 4,353 4,368 4,379 4,389 4,399 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
純有利子負債 -20,790 -21,243 -19,237 - - -9,833 -7,292 -5,530 -6,371 -4,313 -1,711 270 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
DEレシオ(%) 15.34 13.95 14.09 - - 47.05 68.41 100.97 82.31 126.38 579.72 -288.15 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -